{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-000057","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2023-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.751603+00:00","generated_at":"2026-06-20T20:49:19.517211+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aquestive receives Nasdaq deficiency notice for bid price below $1.00","bullets":["Nasdaq notified Aquestive on Dec 30, 2022 that its common stock bid price was below $1.00 for 30 consecutive days.","Company has 180 days, until June 28, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant by deadline, Aquestive may transfer to Nasdaq Capital Market for an additional 180-day cure period.","Company may consider a reverse stock split to address the bid price deficiency.","Failure to regain compliance could result in delisting of AQST common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-000057","json":"https://secwatch.observer/filing/0001628280-23-000057.json","markdown":"https://secwatch.observer/filing/0001628280-23-000057.md","text":"https://secwatch.observer/filing/0001628280-23-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023000057/0001628280-23-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023000057/aqst-20221230.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:49:19.517211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f87bab125097b11361c882569541bf25106e113","claim":"Aquestive Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"December 30, 2022, Aquestive Therapeutics, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has 180 calendar days, or until June 28, 2023, to regain compliance with the Minimum Bid","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023000057/0001628280-23-000057-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}